CIPLA
₹1,470.45
-18 (-1.21%)
19 March, 2024 09:27 BSE: 500087 NSE: CIPLAISIN: INE059A01026

Start SIP in Cipla

Start SIP

Cipla Performance

Day Range

  • Low 1,469
  • High 1,487
₹ 1,470

52 Week Range

  • Low 852
  • High 1,519
₹ 1,470
  • Open Price1,483
  • Previous Close1,488
  • Volume131918

Cipla Share Price

  • Over 1 Month 3.31%
  • Over 3 Month 22.32%
  • Over 6 Month 19.98%
  • Over 1 Year 70.29%

Cipla Key Statistics

P/E Ratio 32.1
PEG Ratio 0.8
Market Cap Cr 118,719
Price to Book Ratio 5
EPS 31.6
Dividend 0.6
Relative Strength Index 58.43
Money Flow Index 41.89
MACD Signal 24.32
Average True Range 32.61
Cipla Financials
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 4,3814,1673,8583,486
Operating Expenses Qtr Cr 3,0253,2863,1143,094
Operating Profit Qtr Cr 1,3561,3791,205800
Depreciation Qtr Cr 135180136162
Interest Qtr Cr 98010
Tax Qtr Cr 363367331206
Net Profit Qtr Cr 1,1141,030895355
IndicatorMar 2023
Total Revenue Annual Cr 16,247
Operating Expenses Annual Cr 11,998
Operating Profit Annual in Cr 3,793
Depreciation Cr 596
Interest Annual Cr 27
Tax Annual Cr 971
Net Profit Annual Cr 2,513
IndicatorMar 2023
Cash from Operating Activity Annual Cr 3,035
Cash from Investing Activity Annual Cr -2,758
Cash from Financing Annual Activity Cr -425
Net Cash Flow Annual Cr -148
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 24,638
Fixed Assets Annual Cr 4,313
Total Non Current Assets Annual Cr 14,225
Total Current Assets Annual Cr 13,371
Total Assets Annual Cr 27,596
IndicatorMar 2023
Book Value Per Share Annual Rs 305
ROE Annual % 10
ROCE Annual % 15
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 27
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 6,6046,5896,2695,666
Operating Expenses Qtr Cr 4,8564,9444,8354,566
Operating Profit Qtr Cr 1,7481,7341,4941,174
Depreciation Qtr Cr 233290239346
Interest Qtr Cr 30261634
Tax Qtr Cr 405438378222
Net Profit Qtr Cr 1,0561,131996522
IndicatorMar 2023
Total Revenue Annual Cr 23,229
Operating Expenses Annual Cr 17,726
Operating Profit Annual in Cr 5,027
Depreciation Cr 1,172
Interest Annual Cr 110
Tax Annual Cr 1,203
Net Profit Annual Cr 2,802
IndicatorMar 2023
Cash from Operating Activity Annual Cr 3,238
Cash from Investing Activity Annual Cr -2,389
Cash from Financing Annual Activity Cr -958
Net Cash Flow Annual Cr -109
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 23,408
Fixed Assets Annual Cr 7,270
Total Non Current Assets Annual Cr 12,188
Total Current Assets Annual Cr 17,275
Total Assets Annual Cr 29,463
IndicatorMar 2023
Book Value Per Share Annual Rs 294
ROE Annual % 12
ROCE Annual % 18
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 24

Cipla Technicals

EMA & SMA

Current Price
₹1,470.45
-18 (-1.21%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹1,470.34
  • 50 Day
  • ₹1,416.85
  • 100 Day
  • ₹1,345.40
  • 200 Day
  • ₹1,253.87
  • 20 Day
  • ₹1,475.71
  • 50 Day
  • ₹1,414.10
  • 100 Day
  • ₹1,320.16
  • 200 Day
  • ₹1,225.45

Cipla Resistance and Support

PIVOT
₹1,485.1
Resistance
First Resistance 1,499.20
Second Resistance 1,509.95
Third Resistance 1,524.05
RSI 58.43
MFI 41.89
MACD Single Line 24.32
MACD 20.56
Support
First Resistance 1,474.35
Second Resistance 1,460.25
Third Resistance 1,449.50

Cipla Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,007,756 64,022,739 63.53
Week 1,596,937 87,751,677 54.95
1 Month 1,540,279 89,428,615 58.06
6 Month 1,745,969 91,366,577 52.33

Cipla Result Highlights

Cipla Synopsis

NSE-Medical-Generic Drugs

Cipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 15790.60 Cr. and Equity Capital is Rs. 161.43 Cr. for the Year ended 31/03/2023. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.
Market Cap 120,173
Sales 17,258
Shares in Float 54.09
No of funds 953
Yield 0.57
Book Value 4.86
U/D Vol ratio 1.5
LTDebt / Equity
Alpha 0.2
Beta 0.16

Cipla

Owner NameDec-23Sep-23Jun-23Mar-23
Promoters 33.47%33.47%33.47%33.55%
Mutual Funds 16.66%16.48%15.35%15%
Insurance Companies 5.34%5.25%6.26%4.74%
Foreign Portfolio Investors 25.73%25.74%25.49%27.42%
Financial Institutions/ Banks 0.13%0.04%0.01%0.11%
Individual Investors 14.33%14.45%14.66%14.85%
Others 4.34%4.57%4.76%4.33%

Cipla Management

Name Designation
Dr. Y K Hamied Chairman
Mr. M K Hamied Vice Chairman
Ms. Samina Hamied Executive Vice Chairman
Mr. Umang Vohra Managing Director & Global CEO
Mr. S Radhakrishnan Non Exe.Non Ind.Director
Mr. Ashok Sinha Independent Director
Mr. P R Ramesh Independent Director
Mr. Robert Stewart Independent Director
Dr. Mandar Vaidya Independent Director
Mr. Adil Zainulbhai Independent Director
Ms. Punita Lal Independent Director

Cipla Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Cipla Corporate Action

Date Purpose Remarks
2024-01-22 Quarterly Results (Revised) per share(150%)Dividend
2023-10-27 Quarterly Results
2023-07-26 Quarterly Results
2023-05-12 Audited Results & Final Dividend
2023-01-25 Quarterly Results
Date Purpose Remarks
2023-07-21 FINAL Rs.8.50 per share(425%)Final Dividend
2022-08-10 FINAL Rs.5.00 per share(250%)Dividend

About Cipla

Cipla Ltd. is a pharmaceutical company in India with a strong global presence. With operations in 80 countries and 47 manufacturing facilities, it sells 1500 products in the market. The largest market of Cipla Ltd. is India, followed by Africa and North America.

The product profile of Cipla Ltd. ranges from drugs in the respiratory, pediatric asthma, nebulisation, anti-retroviral, urology, cardiology, anti-infective, CNS, and several other illnesses and disorders. Cipla's business is divided into three units - Generics and Branded Generics, Specialty and Consumer Health. 

The Generics and Branded Generics unit contributes around 19% of the pharmaceutical revenues in India. The division has 4,000+ partners covering the entire country and is constantly seeking to expand the product portfolio.

The Specialty unit focuses on speciality medicines in respiratory, CNS and critical care. This unit's operations are run under Cipla Technologies LLC (CipTec) and have its headquarters in San Diego, California. 

The Consumer Health Segment focuses on simplifying healthcare and offering simple and over-the-counter solutions to the consumers. A few brands under this business unit are Nicotex, ActivKids ImmunoBoosters, Cofsils, and UnoBiotics.

Cipla was founded in 1935 in Mumbai as Chemical Industrial & Pharmaceutical Laboratories Ltd. by Khwaja Abdul Hamied. The name of the company was changed to Cipla in 1984. It received a major boost in 1985 when the US FDA approved its bulk drug facility. Cipla went on to launch the world's first oral iron chelator in 1995. 

The company acquired the South African company Cipla-Medproin in 2013 and entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa in 2019.

In September 2021, Cipla Ltd. subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation. It is a not-for-profit organisation focused on building digital healthcare infrastructure.

Shareholding Pattern

A total of 230 mutual funds invest in Cipla Ltd., with a total holding of 13.91%. The number of FIIs and FPIs that have invested in it is 786, and their total holding amount to 26.64. These figures are as of March 2022.

The top mutual funds that have invested in Cipla Ltd. are SBI ETF Nifty 50, Baroda BNP Paribas Balanced Advantage Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth, Franklin India Bluechip Fund-Growth and UTI Nifty ETF.

Cipla FAQs

What is Share Price of Cipla ?

Cipla share price is ₹1,470 As on 19 March, 2024 | 09:13

What is the Market Cap of Cipla ?

The Market Cap of Cipla is ₹118719.3 Cr As on 19 March, 2024 | 09:13

What is the P/E ratio of Cipla ?

The P/E ratio of Cipla is 32.1 As on 19 March, 2024 | 09:13

What is the PB ratio of Cipla ?

The PB ratio of Cipla is 5 As on 19 March, 2024 | 09:13

Is it the right time to invest in Cipla?

Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.

Is Cipla an Indian company?

Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.

Who is the CEO of Cipla?

Umang Vohra has been the CEO of Cipla since 1 September 2016.

What is Cipla's stock price CAGR?

Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.

How to buy Cipla Ltd. shares?

You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.

Q2FY23